Omeprazol Basics (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Basics, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat gastro‑oesophageal reflux disease, peptic ulcer disease and to support Helicobacter pylori eradication regimens. GNH USA supplies Omeprazol Basics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders.

Gastro‑oesophageal reflux disease: provides symptomatic relief and promotes healing of esophageal erosion. Peptic ulcer disease: accelerates ulcer healing and reduces recurrence risk. Helicobacter pylori eradication: used as part of combination therapy to increase bacterial eradication rates.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Nausea - Diarrhoea - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis or angioedema - Clostridioides difficile infection - Low magnesium levels (hypomagnesemia) with prolonged use - Increased risk of bone fractures with long‑term therapy - Interstitial nephritis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, consider the following safety measures.

Assess renal function: adjust use in patients with severe impairment. Evaluate for Helicobacter pylori infection before long‑term treatment. Monitor for signs of allergic reaction, especially after first dose. Use the lowest effective dose and shortest duration to minimise fracture risk. Avoid concomitant use with drugs that require gastric acidity for absorption unless medically necessary. Store at room temperature: keep in the original pack, protect from moisture and light.

Omeprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Atazanavir: reduced absorption and efficacy. - Nelfinavir: decreased plasma levels. - Rilpivirine: lowered exposure. - Clopidogrel: impaired activation, reducing antiplatelet effect. - Methotrexate: increased systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: elevated serum concentrations. - Diazepam: enhanced sedation due to higher levels. - Ketoconazole: reduced absorption and effectiveness. - Iron salts: decreased iron uptake, consider spacing administration.